Diligence memo · auto-generated · as of July 2, 2026
hC Bioscience, Inc.
hC Bioscience, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
hC Bioscience, Inc. operates in Biotech, based in Cambridge.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
hC Bioscience, Inc. has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2021-12-03.
Most recent recorded round closed around 2021-12-03.
Valuation (modeled)modeled
Provath models hC Bioscience, Inc. at approximately $431M (range $40M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.33× the median modeled value of Series B Biotech companies in 2019–2021 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.6 yr ago; this sector typically re-raises about every 11 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 90% of Biotech peers (233 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: 54Gene, Inc., Trace Genomics, Inc., Debut Biotechnology, Inc., CRISPR Therapeutics AG.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.